A Phase 2 interventional study of Nivolumab and Relatlimab in Hepatocellular Carcinoma, Hepatoma and Liver Cancer, Adult, sponsored by Bristol-Myers Squibb. Completed at 65 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 9th largest by enrollment, is one of 5 that started in 2021, is one of 28 in phase 2, and was the 35th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Hawaii · Sites in United States
Ages 18+
West China Hospital · Sites in China
Ages 18–80
Diwakar Davar · Sites in United States
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 36 · Phase 3 6
First in 2012; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 266 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 53 interventional studies. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 53 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb: 3 open now, 4 under way, 1 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 16th registered.
Bristol-Myers Squibb’s Carcinoma, Hepatocellular studies by the year they started, since 2006.
5 of the studies testing nivolumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04472767University of California, IrvineCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | 2027-01-31 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT07919717Shanghai Zhongshan HospitalNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | 2027-05-12 |
| NCT07075120University of HawaiiIpilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | 2027-08-01 |
| NCT05475613Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab
Biological: Nivolumab · Biological: Relatlimab
Biological: Nivolumab · Biological: Relatlimab
Specified dose on specified days
Also known as: OPDIVO, BMS-936558
Specified dose on specified days
Also known as: BMS-986016
Objective Response Rate(ORR) Assessed by BICR
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Disease Control Rate Assessed by BICR
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by BICR
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by BICR
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Objective Response Rate Assessed by Investigator
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on investigator assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Disease Control Rate Assessed by Investigator
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Duration of Response Assessed by Investigator
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the investigator, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Progression Free Survival(PFS) Assessed by Investigator
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization to the date of death from any cause. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Adverse Events
Number of participants with an Adverse Event. An Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Serious Adverse Events
Number of participants with Serious Adverse Events A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Adverse Events Leading to Discontinuation
Number of participants with Adverse Events Leading to Discontinuation
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Death Summary
Number of participants who died.
Time frame: From randomization to primary completion date (Approximately 29.5 Months)
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
Number of participants with clinical laboratory abnormalities in specific liver tests
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
Number of Participants With Clinical Laboratory Abnormalities in Thyroid Tests
Number of participants with clinical laboratory abnormalities in thyroid tests
Time frame: From randomization to primary completion date (Approximately 29.5 Months). Includes events reported between first dose and 30 days after last dose of study therapy.
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 128 | 114 | 24 |
| Completed | 127 | 113 | 24 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 1 | 0 |
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 127 | 113 | 24 |
| Completed | 3 | 1 | 0 |
| Not completed | 124 | 112 | 24 |
| Withdrew: Participant withdrew consent | 2 | 5 | 1 |
| Withdrew: Death | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 | 0 |
| Withdrew: Disease progression | 85 | 63 | 16 |
| Withdrew: Study drug toxicity | 3 | 10 | 4 |
| Withdrew: Adverse event unrelated to study drug | 11 | 6 | 1 |
| Withdrew: Other reasons | 1 | 2 | 0 |
| Withdrew: Still on-going treatment | 21 | 22 | 2 |
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
| Percentage | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Objective Response Rate(ORR) Assessed by BICR | 13.3 (7.9 to 20.4) | 10.5 (5.6 to 17.7) | 12.5 (2.7 to 32.4) |
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
| Percentage | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Disease Control Rate Assessed by BICR | 44.5 (35.7 to 53.6) | 44.7 (35.4 to 54.3) | 33.3 (15.6 to 55.3) |
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
| Months | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Duration of Response Assessed by BICR | 5.82 (5.55 to NA) | NA (5.32 to NA) | NA (7.39 to NA) |
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.
| Months | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Progression Free Survival(PFS) Assessed by BICR | 2.00 (1.91 to 3.75) | 2.00 (1.87 to 3.71) | 1.94 (1.74 to 3.71) |
Objective Response Rate (ORR) (as per Recists v1.1) is defined as the percentage of participants whose best overall response (BOR) is either confirmed complete response (CR) or confirmed partial response (PR) based on investigator assessments among all participants in the respective analysis set. BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of first objectively documented progression or death due to any cause or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. Confirmation of response is required at least 4 weeks after the initial response.
| Percentage | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Objective Response Rate Assessed by Investigator | 14.1 (8.6 to 21.3) | 13.2 (7.6 to 20.8) | 20.8 (7.1 to 42.2) |
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.
| Percentage | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Disease Control Rate Assessed by Investigator | 48.4 (39.5 to 57.4) | 50.9 (41.3 to 60.4) | 41.7 (22.1 to 63.4) |
Duration of Response (DOR) (as per Recists v1.1) is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the investigator, or death due to any cause, whichever occurs first. Participants who die without a reported prior progression will be considered to have an event on the date of their death. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
| Months | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Duration of Response Assessed by Investigator | 10.94 (4.63 to NA) | NA (5.55 to NA) | 12.42 (3.61 to NA) |
PFS (as per Recists v1.1) is defined as the time between the date of randomization and the date of first documented tumor progression or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death.
| Months | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Progression Free Survival(PFS) Assessed by Investigator | 3.32 (2.00 to 4.01) | 3.65 (1.97 to 4.30) | 1.94 (1.68 to 3.75) |
Overall survival (OS) is defined as the time from randomization to the date of death from any cause. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up.
| Months | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Overall Survival (OS) | 12.68 (9.40 to 18.76) | 12.19 (9.49 to 14.52) | 8.21 (4.76 to 16.92) |
Number of participants with an Adverse Event. An Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants With Adverse Events | 119 | 108 | 22 |
Number of participants with Serious Adverse Events A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants With Serious Adverse Events | 43 | 46 | 14 |
Number of participants with Adverse Events Leading to Discontinuation
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | 13 | 14 | 5 |
Number of participants who died.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Death Summary | 67 | 60 | 18 |
Number of participants with clinical laboratory abnormalities in specific liver tests
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| ALT OR AST> 5XULN | 25 | 41 | 6 |
| ALT OR AST> 10XULN | 7 | 16 | 2 |
| TOTAL BILIRUBIN > 2XULN | 17 | 14 | 2 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN >2XULN WITHIN 30 DAYS | 14 | 10 | 1 |
Number of participants with clinical laboratory abnormalities in thyroid tests
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| TSH > ULN | 38 | 42 | 2 |
| TSH > ULN WITH TSH ≤ ULN AT BASELINE | 14 | 18 | 1 |
| TSH <LLN WITH TSH ≥ LLN AT BASELINE | 16 | 26 | 2 |
Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose to primary completion date) : Approximately 29.5 months All-Cause mortality (From randomization to primary completion date): Approximately 29.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 68/128 (53.1%) | 65/127 (51.2%) | 104/127 (81.9%) |
| Treatment B | 60/114 (52.6%) | 65/113 (57.5%) | 102/113 (90.3%) |
| Treatment C | 18/24 (75%) | 20/24 (83.3%) | 22/24 (91.7%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 29/127 | 24/113 | 6/24 |
| MyocarditisCardiac disorders | 0/127 | 1/113 | 2/24 |
| AscitesGastrointestinal disorders | 3/127 | 3/113 | 1/24 |
| Colitis microscopicGastrointestinal disorders | 0/127 | 0/113 | 1/24 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/127 | 0/113 | 1/24 |
| PancreatitisGastrointestinal disorders | 0/127 | 0/113 | 1/24 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/127 | 0/113 | 1/24 |
| PyrexiaGeneral disorders | 2/127 | 1/113 | 1/24 |
| HypersensitivityImmune system disorders | 0/127 | 0/113 | 1/24 |
| COVID-19 pneumoniaInfections and infestations | 0/127 | 0/113 | 1/24 |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 33/127 | 33/113 | 3/24 |
| AstheniaGeneral disorders | 16/127 | 9/113 | 7/24 |
| AnaemiaBlood and lymphatic system disorders | 21/127 | 16/113 | 6/24 |
| DiarrhoeaGastrointestinal disorders | 11/127 | 20/113 | 6/24 |
| Alanine aminotransferase increasedInvestigations | 21/127 | 27/113 | 3/24 |
| PruritusSkin and subcutaneous tissue disorders | 24/127 | 16/113 | 4/24 |
| Oedema peripheralGeneral disorders | 17/127 | 20/113 | 2/24 |
| AscitesGastrointestinal disorders | 6/127 | 11/113 | 4/24 |
| Decreased appetiteMetabolism and nutrition disorders | 10/127 | 15/113 | 4/24 |
| RashSkin and subcutaneous tissue disorders | 8/127 | 12/113 | 4/24 |
All Randomized Participants
| Age, Continuous(Years) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Mean | 64.0 ± 10.4 | 63.3 ± 11.2 | 68.1 ± 10.9 | 64.1 ± 10.8 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Female | 23 | 21 | 2 | 46 |
| Male | 105 | 93 | 22 | 220 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 16 | 0 | 30 |
| Not Hispanic or Latino | 65 | 47 | 15 | 127 |
| Unknown or Not Reported | 49 | 51 | 9 | 109 |
| Race/Ethnicity, Customized(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| White | 61 | 54 | 12 | 127 |
| Black or African American | 2 | 1 | 0 | 3 |
| Asian | 28 | 19 | 2 | 49 |
| American Indian or Alaska Native | 5 | 6 | 0 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Other | 3 | 5 | 0 | 8 |
| Chinese | 16 | 16 | 4 | 36 |
| Japanese | 7 | 4 | 3 | 14 |
| Malay | 0 | 1 | 0 | 1 |
| Asian Other | 6 | 8 | 2 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2021 to primary completion in Aug 2023, 30 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 30 months is below that.
Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab